ABOUT EDDC

At the Early Drug Development Center (EDDC) we are entirely focused on early clinical research, meaning phase 1 and phase 2 studies are being conducted. We have been established as a separate and more specialized unit within the Netherlands Cancer Institute (NKI). The EDDC is fully equipped for efficient and reliable execution of early clinical research. This unit can serve as a professional partner for multidisciplinary working groups, supported with medical, administrative, and nursing assistance.
Patients from all over the Netherlands and abroad are being referred to join the early drug development program. It is our ambition to have every new drug (class) available for our patients by participating in high-impact phase 1 and 2 studies. We have been able to realize this goal for the past twenty years, and we will continue to do so for the benefit of our patients. We work together with our pharmacy, which also includes a large bio-analytical laboratory, drug formulation, GMP production- and research facilities.

With energy and enthusiasm, we are committed to our patients and the realization of our mission: through the combination of care, research, and (international) exchange of knowledge, we make a significant contribution to solve the cancer problem in the 21st century. You can have a look at our team on this page.

You can find a list of clinical trials that are currently being performed here. Moreover, if you are interested in getting to know EDDC better, you can also visit the page about Facilities and resources that work closely with this unit.

What does EDDC do?